A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis

NCT00172107 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

217

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoporosis

Interventions

DRUG: ALX1-11 50 mcg
DRUG: placebo
DRUG: ALX1-11 75mcg
DRUG: ALX1-11

Sponsor

Shire